SQZ Biotechnologies Profit Margin

SQZ Biotechnologies (SQZ) currently reports a profit margin of -27.85% as of September 2023. That compares with -361.87% in the prior-year period — up 92.3% year over year. That is below the Healthcare sector average of 10.58%. Use the charts on this page to explore SQZ Biotechnologies's profit margin history and peer comparisons.

SQZ Biotechnologies's profit margin increased from -361.87% to -27.85% — a 92.3% year-over-year increase (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

SQZ Biotechnologies's profit margin of -27.85% is lower than the Healthcare sector average of 10.58%. That is roughly 363.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but SQZ Biotechnologies's current -27.85% should be judged against Healthcare norms (sector average: 10.58%) and against SQZ's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -27.85%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 10.58%. From there, open related valuation or income-statement pages for SQZ Biotechnologies, and consider following SQZ for alerts when major investors trade the stock.